ERUDITE PHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
What changed
ERUDITE PHARMA
NACE 47.730, Retail sale of pharmaceutical products
fiscal year 2024 against 2025filed annual accounts (NBB)
Net result for the year
-€17,585
2024 · -€6,227-€11,357
Equity
€340,033
2024 · €357,618-€17,585
Cash
€68,300
2024 · €61,679+€6,620
Balance sheet total
€1.4m
2024 · €1.5m-€61,916
Largest movements
Assets
- Tangible fixed assets -€67,407
down €67,407 (-6.0%), from €1.1m to €1.1m
of which Land and buildings: -€51,820
Equity and liabilities
- Debts after one year -€56,364
down €56,364 (-9.5%), from €590,808 to €534,443
- Profit (loss) carried forward -€17,585
down €17,585 (-4.7%), from -€375,400 to -€392,985
- Trade debts +€16,606
up €16,606 (+30.5%), from €54,400 to €71,006
Income statement
- Staff costs +€12,794
up €12,794 (+10.2%), from €125,838 to €138,632
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Result 2024
-€6,227
Gross operating margin
+€1,526
Staff costs
-€12,794
Depreciation
-€221
Other operating charges
-€171
Other operating items
+€500
Financial income
+€530
Financial charges
-€727
Result 2025
-€17,585
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
From operations
+€62,645
Investment
€0
Financing
-€56,024
Cash 2024
€61,679
From operations (derived)
+€62,645
Net result for the year
-€17,585
Depreciation
+€67,407
Stocks and contracts
+€10,291
Receivables within one year
-€7,189
Deferred charges and accrued income
-€1,972
Trade debts
+€16,606
Tax, wage and social debts
+€5,544
Other debts
-€12,000
Accrued charges and deferred income
+€1,543
Financing
-€56,024
Debts after one year
-€56,364
Current portion of long-term debt
+€340
Cash 2025
€68,300
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,465,555 | €1,403,639 | -€61,916 | -4.2% |
| Fixed assets | 21/28 | €1,127,544 | €1,060,137 | -€67,407 | -6.0% |
| Tangible fixed assets | 22/27 | €1,127,544 | €1,060,137 | -€67,407 | -6.0% |
| Land and buildings | 22 | €1,011,692 | €959,872 | -€51,820 | -5.1% |
| Plant, machinery and equipment | 23 | €115,852 | €100,264 | -€15,588 | -13.5% |
| Current assets | 29/58 | €338,011 | €343,502 | +€5,491 | +1.6% |
| Stocks and contracts in progress | 3 | €194,348 | €184,057 | -€10,291 | -5.3% |
| Stocks | 30/36 | €194,348 | €184,057 | -€10,291 | -5.3% |
| Amounts receivable within one year | 40/41 | €80,680 | €87,869 | +€7,189 | +8.9% |
| Trade receivables | 40 | €79,957 | €84,983 | +€5,026 | +6.3% |
| Other amounts receivable | 41 | €723 | €2,886 | +€2,163 | +299.0% |
| Cash at bank and in hand | 54/58 | €61,679 | €68,300 | +€6,620 | +10.7% |
| Deferred charges and accrued income | 490/1 | €1,304 | €3,276 | +€1,972 | +151.3% |
| Total equity and liabilities | 10/49 | €1,465,555 | €1,403,639 | -€61,916 | -4.2% |
| Equity | 10/15 | €357,618 | €340,033 | -€17,585 | -4.9% |
| Contributions | 10/11 | €730,881 | €730,881 | = | 0.0% |
| Reserves | 13 | €2,137 | €2,137 | = | 0.0% |
| Tax-exempt reserves | 132 | €20 | €20 | = | 0.0% |
| Distributable reserves | 133 | €2,117 | €2,117 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€375,400 | -€392,985 | -€17,585 | -4.7% |
| Amounts payable | 17/49 | €1,107,937 | €1,063,606 | -€44,332 | -4.0% |
| Amounts payable after more than one year | 17 | €590,808 | €534,443 | -€56,364 | -9.5% |
| Financial debts | 170/4 | €590,808 | €534,443 | -€56,364 | -9.5% |
| Amounts payable within one year | 42/48 | €514,384 | €524,873 | +€10,489 | +2.0% |
| Current portion of amounts payable after more than one year | 42 | €56,024 | €56,364 | +€340 | +0.6% |
| Trade debts | 44 | €54,400 | €71,006 | +€16,606 | +30.5% |
| Suppliers | 440/4 | €54,400 | €71,006 | +€16,606 | +30.5% |
| Taxes, remuneration and social security | 45 | €7,362 | €12,906 | +€5,544 | +75.3% |
| Taxes | 450/3 | €145 | - | -€145 | |
| Remuneration and social security | 454/9 | €7,218 | €12,906 | +€5,689 | +78.8% |
| Other amounts payable | 47/48 | €396,597 | €384,597 | -€12,000 | -3.0% |
| Accrued charges and deferred income | 492/3 | €2,746 | €4,289 | +€1,543 | +56.2% |
| Remuneration, social security and pensions | 62 | €125,838 | €138,632 | +€12,794 | +10.2% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €67,186 | €67,407 | +€221 | +0.3% |
| Other operating charges | 640/8 | €1,379 | €1,551 | +€171 | +12.4% |
| Non-recurring operating charges | 66A | €500 | - | -€500 | |
| Gross operating margin | 9900 | €193,438 | €194,964 | +€1,526 | +0.8% |
| Operating profit (loss) | 9901 | -€1,467 | -€12,626 | -€11,160 | -760.9% |
| Financial income | 75/76B | €1,855 | €2,384 | +€530 | +28.6% |
| Recurring financial income | 75 | €1,855 | €2,384 | +€530 | +28.6% |
| Financial charges | 65/66B | €6,616 | €7,343 | +€727 | +11.0% |
| Recurring financial charges | 65 | €6,616 | €7,343 | +€727 | +11.0% |
| Profit (loss) for the period before taxes | 9903 | -€6,227 | -€17,585 | -€11,357 | -182.4% |
| Profit (loss) for the period | 9904 | -€6,227 | -€17,585 | -€11,357 | -182.4% |
| Profit (loss) for the period to be appropriated | 9905 | -€6,227 | -€17,585 | -€11,357 | -182.4% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 8 October 2026 via checked.be.